Episode 4: Excitotoxins that Fuel Cancer, Nature’s Pharmacy and Healing Cancer with Sound & Light
Category: Cancer Genomics
What do you think. Is it correct and if, yes what if a person does not have 45 years of life left?? Physician Who Gave Unneeded Chemo Gets 45 Years in Prison
Physician Who Gave Unneeded Chemo Gets 45 Years in Prison.
Farid Fata, MD, the oncologist who got rich administering excessive or unnecessary chemotherapy to hundreds of patients, including some who did not have cancer, was sentenced to 45 years in prison today by a federal judge in Detroit, Michigan.
The sentence came after the 50-year-old Dr Fata heard the judgement of patients and family members who testified earlier this week to the excruciating physical and psychological harm he caused.
One of them was Laura Stedtefelt, who said the oncologist had overtreated her late father for lung cancer to the point of killing him, according to an account in the Detroit Free Press.
“I hate you,” said Stedtefelt, addressing Dr Fata. “You are a monster. You are evil. You poisoned him. You tortured and murdered my dad.”
Former patient Maggie Dorsey testified that Dr Fata deliberately misdiagnosed her with a type of blood cancer called multiple myeloma and treated her with the chemotherapy agent bortezomib. She tearfully described living with the adverse effects, which include severe osteoporosis and neuropathy.
What do you think. is it correct and if yes what if a person does not have 45 years of life left??
False breast cancer alarm can affect women for years!
London: The psychological strain of being informed that you may have breast cancer may be severe even if it turns out to be a false alarm, a study has found.
Read More “False breast cancer alarm can affect women for years!”
News Today: Angelina Jolie has ovaries and fallopian tubes removed-But Hold on
Link to the news::: Who needs the tests such as this and what is the significance and take of masters in science. There are two tests or may be panels or gens or serum markers as we may call them in question. First is CA 125 Serum Marker and the other is the Mutation test in two genes called as BRCA 1 and BRCA 2. what they mean and how the test should be elective and who may or may not undergo such an exercise. This news rocks the hollywood but is also starting to haunt women across the globe the second time. Read on
Read More “News Today: Angelina Jolie has ovaries and fallopian tubes removed-But Hold on”
Complementary, Alternative, and Integrative Medicine-Some modalities will garner sufficient support to become part of mainstream care and the next generation of physicians will never know they were once controversial.
The side picture to this post is indicative of all about the essential elements of the integrative medicine wheel to include Energy Medicine, Mind/Body Medicine, Manipulative Therapies, Herbal Medicine, Lifestyle and behaviour. Medicine and medical professional in the current generation is arguably a team of specialists and allied professionals—radiation physicists, cytologists, nurse practitioners, psychiatric social workers, dental hygienists, and many more.TA common man’s expectations of health and the nature of the health care system have been altered and is frequently guided by information, goods, and services ; regulations and laws that constrain medical practice on the one hand and rarely accelerating choice in health care on the other.
Module 3A: Cancer and its basics- for laymen,believers and followers
During my education and endeavours in medicine, I read Betty S quote once that Where there is life, there is cancer. Although the types of cancer and their incidence (the number of new types diagnosed each year) may vary by geography, sex, race, age, and ethnicity, cancer exists in every population and has since ancient times.
Read More “Module 3A: Cancer and its basics- for laymen,believers and followers”
The hypothalamus is a crucial region for integrating signals from central and peripheral pathways and plays a major role in Appetite regulation.
The hypothalamus is a crucial region for integrating signals from central and peripheral pathways and plays a major role in Appetite regulation.
Combine and Conquer | Therapy yields reduction in HER2+ breast cancer recurrence
Therapy yields reduction in HER2+ breast cancer recurrence
Image: iStock/AngiePhotos
In a phase two clinical trial, women with small (stage one) HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were highly unlikely to have the cancer recur within three years of treatment, investigators at Harvard Medical School and Dana-Farber Cancer Institute report in a paper published Jan. 7 in the New England Journal of Medicine.
The findings may help establish the therapy—which combines the chemotherapy agent paclitaxel and the targeted drug trastuzumab (Herceptin)—as the first standard treatment approach for this group of patients, the authors state.
Many previous studies excluded women with small HER2-positive breast tumors that hadn’t spread to nearby lymph nodes from clinical trials of trastuzumab because it wasn’t considered prudent to expose them to an investigational drug given the relatively low risk that the disease would recur. Without a single standard treatment for this group of patients, treatment approaches have varied widely. Breast cancers are classified as HER2-positive if their cells have surplus human epidermal growth factor receptors on their surface, making them extra sensitive to signals to grow and divide.
“Women with small HER2 positive, node-negative breast tumors have a low, but still significant, risk of recurrence of their disease,” said the study’s senior author, Eric Winer, HMS professor of medicine and director of the Breast Oncology Program at the Susan F. Smith Center for Women’s Cancers at Dana-Farber. “This study demonstrates that a combination of lower-intensity chemotherapy and trastuzumab—which is associated with fewer side effects than traditional chemotherapy regimens—is an appealing standard of care for this group of patients.”
The study enrolled 406 patients with HER2-positive, node-negative breast tumors smaller than 3 centimeters. They were treated with the drug combination for 12 weeks, followed by nine months of trastuzumab alone. Traditional drug regimens for women with HER2-positive breast cancer involve chemotherapy with adriamycin and cytoxan followed by paclitaxel and trastuzumab.
Three years after completing therapy, 98.7 percent of the participants were alive and free of invasive breast cancer. The side effects were generally milder than those associated with traditional chemotherapy regimens.
“We’re committed to identifying treatment regimens that are geared not only to the specific biological features of a woman’s cancer, but also to the stage of the cancer—the size of the tumor and how far it has advanced,” said the study’s lead author, Sara Tolaney, HMS instructor in medicine at the Susan F. Smith Center. “This study is a prime example of the value of that approach.”
Financial support for the research was provided by Genentech and Susan G. Komen for the Cure.
Adapted from a Dana-Farber news release.
May i propose all Indian companies interested to fall in and make a consortium to help support. appeal to all those out there across India?
New Companies Join Cancer Research UK Consortium |
| Published: Thursday, December 11, 2014 Last Updated: Thursday, December 11, 2014 |
| Three new biomarker companies have been selected to work with the Early Diagnosis Consortium, a collaboration between Cancer Research UK, its commercial arm, Cancer Research Technology and Abcodia. |
| The decision follows completion of a pilot phase to evaluate leading technologies for their ability to discover biomarkers that can detect cancer in its earliest stages, long before symptoms appear, when treatment is most likely to be effective. The technologies were tested against serum samples selected from a biobank of more than five million serum samples, collected from women as part of the UKCTOCS trial, to which Abcodia has exclusive commercial access.
Based on these findings, the three companies involved will be Caprion which specialises in proteomics, Asuragen which uses next-generation sequencing to find circulating microRNAs, and the AIT Austrian Institute of Technology using its tumour auto-antibodies platform. This next stage of the programme will focus on identifying biomarkers for colorectal, lung, oesophageal and pancreatic cancers, chosen because of the limited availability of screening tests for these cancers and patients’ poor survival when diagnosed at a late stage. Dr Julie Barnes, chief executive of Abcodia, said: “We are excited to work with these world leading companies to bring their cutting edge technology to this endeavour. The application of such technologies to biomarker discovery in longitudinal samples donated before the clinical presentation of cancer is a real innovation and has the potential to make a real difference to the field of early cancer detection.” Professor Ian Jacobs, vice president at the University of Manchester, principal investigator of UKCTOCS and one of the founders of Abcodia, said: “Cancers that are diagnosed at a later stage are much more difficult to manage, so I am delighted to see the progress that this consortium is making. The experiments aimed at identifying biomarkers that could form simple, non-invasive tests for early cancer detection represent an ideal use of the biobank developed through UKCTOCS.” Dr Keith Blundy, chief executive of Cancer Research Technology, said: “After a successful pilot, we are delighted to be able to bring additional technological capability into this collaborative effort, to add to the clinical, scientific and commercial expertise of existing partners. The biobank derived from UKCTOCS is providing us with the opportunity, through this initiative, to potentially unlock a future in which thousands of cancer cases could be detected and treated before symptoms emerge.” |
Senior Citizen alert Who are taking (ACE) inhibitor or an angiotensin receptor blocker (ARB) hypertension drugs!
Please note that all elder persons who are taking the above may have a problem with c-administration of this antibacterial drug called as Trimethoprim-sulfamethoxazole combination.
While trimethoprim-sulfamethoxazole (TMP-SMX) has generally been felt to be well tolerated, a case-control study found an association between sudden death, possibly due to hyperkalemia, and prescription of TMP-SMX among older patients who were also receiving an angiotensin converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB).
While trimethoprim-sulfamethoxazole (TMP-SMX) has generally been felt to be well tolerated, a case-control study found an association between sudden death, possibly due to hyperkalemia, and prescription of TMP-SMX among older patients who were also receiving an angiotensin converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB).
Hypertension has been well studied and reported in the setting of other cancer therapies. The importance of adequately diagnosing and managing hypertension in patient population arises from the facts that hypertension is well established as a risk factor for chemotherapy-induced cardiotoxicity and that poorly controlled hypertension can significantly influence cancer management and even lead to the discontinuation of certain therapies. Thanks
END YOUR ILLNESS 